跳至主要内容
临床试验/ACTRN12605000208606
ACTRN12605000208606已完成4 期

A two year double blind, randomised, controlled trial to evaluate the efficacy of zoledronic acid in the prevention of bone loss in patients infected with human immunodeficiency virus taking highly active antiretroviral therapy (HAART)

Associate Professor A Grey0 个研究点目标入组 70 人开始时间: 2005年8月25日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
ot stated 至 ot stated(—)
性别
Male

入选标准

  • HIV positive and have taken HAART for at least 3 months and have a bone mineral density T score of less than -0.5SD at any site.

排除标准

  • Renal impairment (serum creatinine >0.15 mmol/L), untreated hypothyroidism or hyperthyroidism, chronic liver disease, concurrent major systemic illness, including malignancy, active major gastrointestinal disease, metabolic bone diseases, primary hyperparathyroidism, more than 2 hospital admissions within 6 months of study entry, use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding six months.

研究者

发起方
Associate Professor A Grey

相似试验